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Abstract
Background: Dysglycemia is a major risk factor for atherosclerosis. In many patient populations dysglycemia is
under-diagnosed. Patients with severe coronary artery disease commonly have dysglycemia and there is growing
evidence that dysglycemia, irrespective of underlying history of diabetes, is associated with adverse outcome in
coronary artery bypass graft (CABG) surgery patients, including longer hospital stay, wound infections, and higher
mortality. As HbA1c is an easy and reliable way of checking for dysglycemia we routinely screen all patients
undergoing CABG for elevations in HbA1c. Our hypothesis was that a substantial number of patients with
dysglycemia that could be identified at the time of cardiothoracic surgery despite having no apparent history of
diabetes.
Methods: 1045 consecutive patients undergoing CABG between 2007 and 2009 had HbA1c measured pre-
operatively. The 2010 American Diabetes Association (ADA) diagnostic guidelines were used to categorize patients
with no known history of diabetes as having diabetes (HbA1c ≥ 6.5%) or increased risk for diabetes (HbA1c 5.7-
6.4%).
Results: Of the 1045 patients with pre-operative HbA1c measurements, 40% (n = 415) had a known history of
diabetes and 60% (n = 630) had no known history of diabetes. For the 630 patients with no known diabetic
history: 207 (32.9%) had a normal HbA1c (< 5.7%); 356 (56.5%) had an HbA1c falling in the increased risk for
diabetes range (5.7-6.4%); and 67 (10.6%) had an HbA1c in the diabetes range (6.5% or higher). In this study the
only conventional risk factor that was predictive of high HbA1c was BMI. We also found a high HbA1c irrespective
of history of DM was associated with severe coronary artery disease as indicated by the number of vessels
revascularized.
Conclusion: Among individuals undergoing CABG with no known history of diabetes, there is a substantial
amount of undiagnosed dysglycemia. Even though labeling these patients as “diabetic” or “increased risk for
diabetes” remains controversial in terms of perioperative management, pre-operative screening could lead to
appropriate post-operative follow up to mitigate short-term adverse outcome and provide high priority medical
referrals of this at risk population.
Keywords: HbA1c, coronary artery bypass grafting (CABG), coronary artery disease (CAD), dysglycemia, increased
risk of diabetes, diabetes
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Diabetes Mellitus (DM) is a major risk factor for the
development of vascular disease, including coronary
artery disease (CAD) [1-6]. Still, up to one third of
patients with diabetes remain undiagnosed and may
remain so for years, since the slowly progressing dysgly-
cemic phase of this disease does not typically produce
symptoms [7]. Earlier identification of asymptomatic
dysglycemic patients may lead to more timely interven-
tions and treatment to prevent or delay end-organ
damage, and life-style modification and/or medication
m a yr e d u c et h ep r o g r e s s i o no fi n c r e a s e dr i s kf o rd i a -
betes into diabetes [8].
Identifying dysglycemia may be accomplished with an
overnight fasting blood glucose, a two hour oral glucose
tolerance test, and more recently the American Diabetes
Association (ADA) indicated hemoglobin A1C (HbA1c)
testing is an acceptable alternative for diagnosing dysgly-
cemia [9]. The HbA1c has the following advantages over
glucose based tests: it is not necessary to fast before
testing; the test can be obtained in acute care settings;
and the time of day of the blood drawn is not relevant.
Patients with coronary artery disease are at a high risk
for having dysglycemia. There is growing evidence that
dysglycemia irrespective of underlying history of dia-
betes is associated with adverse outcomes in coronary
artery bypass graft (CABG) surgery patients, including
increased length of stay, wound infections and higher
mortality [10-12]. We propose that pre-operative assess-
ment of patients undergoing CABG surgery presents an
opportunity for identifying adults with previously
undiagnosed dysglycemia and might lead to appropriate
post-operative follow up to mitigate short-term adverse
outcome and high priority medical referral of this at risk
population since earlier diagnosis of diabetes can poten-
tially prevent long-term complications. The goal of this
study was to determine the prevalence of undiagnosed
dysglycemia as defined by the HbA1c level among
patients undergoing CABG.
Methods
Patients presenting to a community tertiary hospital for
cardiac surgery between the years 2007 and 2009 had
HbA1c assayed during the pre-operative assessment.
According to our surgical protocol HbA1c is routinely
obtained pre-operatively, whether patients have a known
history of diabetes or not. Patients were included if they
were undergoing CABG with or without valve replace-
ment and had a pre-operative HbA1c value recorded.
Data was retrospectively obtained from the medical
charts and the center’s Centricity Cardiology Data Man-
agement System Society of Thoracic Surgeons (STS)
Adult Cardiac database (version 2.52.1 and 2.61). The
HbA1c was assayed in the Staten Island University
Hospital clinical laboratory using the Tosoh G7 analyzer
(Tokyo, Japan).
The main objective of this study was to determine the
prevalence of dysglycemia in patients undergoing CABG
who had no known history of diabetes. We used the
2010 ADA guidelines for HbA1c identification of
patients with potential dysglycemia [9]. A HbA1c of
6.5% or higher categorizes patients as having “diabetes”,
a HbA1c of 5.7-6.4% categorizes patients as “increased
risk for diabetes” and a HbA1c level less than 5.7% is
considered normal. We also determined the total preva-
lence of “diabetes” and “increased risk for diabetes” in
all patients undergoing CABG by combining patients
with known diabetes into the total count. Descriptive
statistics, chi-square and analysis of variance were used
to analyze the data; analyses were conducted using Sta-
tistical Analysis System (SAS) version 9.2. A p-value
equal to 0.05 was considered statistically significant. The
study was approved by the Staten Island University
Institutional Review Board.
Results
1157 patients underwent CABG during the three year
study period of which 1045 had a pre-operative HbA1c
level documented in the medical records. Of the 1045
patients with a recorded HbA1c, 415/1045 (40%) had a
known history of DM and 630/1045 (60%) had no
known history of DM (Table 1). The distribution of
HbA1c for all 1045 patients is found in Table 2.
The following results are for the 630 patients with no
known history of DM. The average patient age was 65.4
years, 148/630 (24%) were female and 571/630 (91%)
were white. Table 1 includes additional patient charac-
teristics and medical history. The subjects included in
this study had an average body mass index (BMI) of
28.3 kg/m
2, 77% had a history of hypertension, and 46%
had a previous myocardial infarction. The mean number
of vessels surgically revascularized in this group was 3.1.
T h em a i ns t u d yf i n d i n g sa r er e p o r t e di nT a b l e2 .A
total of 207/630 (32.9%) patients were found to have a
HbA1c in the normal range, 356/630 (56.5%) had an
HbA1c in the “increased risk for diabetes” range and 67
(10.6%) patients had an HbA1c in the diabetes range.
Table 3 indicates the relationship between selected
risk factors and HbA1c. We found no differences in age,
gender, insurance status, or personal medical history
between the normal and study determined pre-diabetic
and diabetic groups. The proportion of patients with a
history of myocardial infarction increased with increas-
ing HbA1c (40.6% of those in the normal category and
50.8% of those in the diabetic category), although this
trend was not significant. The mean BMI increased sig-
nificantly with increasing HbA1c, and those whose
HbA1c indicated diabetes had more vessels
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and pre-diabetic groups (mean 3.1, p = 0.009).
We identified the scope of dysglycemia among all
1045 patients undergoing CABG, which included
patients with a known history of diabetes. A total of
482/1045 (46%) of all patients undergoing CABG were
identifiable as having diabetes, including the 415 known
diabetic patients and the 67 newly discovered diabetic
patients. On evaluation of the frequency of dysglycemia
in patients undergoing CABG, we found that 838/1045
(80%) of all patients had either a history of known dia-
betes or an elevated HbA1c (>5.7%) at the time of
surgery.
Discussion
We found undiagnosed dysglycemia is common among
patients having coronary revascularization surgery, with
67% of patients newly diagnosed at the time of CABG
surgery. This includes 57% of patients meeting the cri-
teria for increased risk for diabetes (HbA1c 5.7-6.4%)
and 11% of patients meeting criteria for diabetes
(HbA1c greater or equal to 6.5%). Recent evidence that
dysglycemia irrespective of underlying history of dia-
betes is associated with adverse outcome in CABG
patients, including longer hospital stay, wound infections
and higher mortality, may by itself justify the need for
screening [10-12]. This is in addition to any long term
benefit provided by earlier medical referral and manage-
ment of newly diagnosed patients. The study data also
highlights the very common association of dysglycemia
with coronary artery disease, since when including the
previously and newly diagnosed patients, a total of 80%
of all patients undergoing CABG have dysglycemia.
Our findings that elevated HbA1c levels are common
among patients requiring surgical revascularization with
no known history of diabetes are supported by large stu-
dies of patients presenting with acute coronary syn-
drome, where a consistently high frequency of
undiagnosed dysglycemia using glucose-based testing
has been reported [1,13-15]. Based on the strong asso-
ciation of symptomatic CAD and diabetes, the European
Society of Cardiology recommends diabetes screening
for all patients hospitalized with acute coronary syn-
drome [16]. There are fewer studies that report screen-
ing for undiagnosed diabetes or pre-diabetes among
patients undergoing CABG. In Sweden, among 267
patients undergoing CABG and without a known dia-
betes history, 73% were found by oral glucose tolerance
testing (OGTT) to have either pre-diabetes or diabetes
Table 1 Patient characteristics of overall CABG sample
and with no known history of diabetes mellitus
N = 1045 n = 630*
Age (years) Mean 64.9 (± 10.9) Mean 65.4 (± 11.1)
Gender (female, %) 258 (24.7%) 148 (23.5%)
Race Caucasian 902
(86.3%)
Caucasian 571
(90.6%)
Black 38 (3.6%) Black 19 (3%)
Asian 22 (2.1%) Asian 9 (1.4%)
Other 71 (6.8%) Other 29 (4.6%)
Insurance Status Medicare 527
(50.4%)
Medicare 326
(51.8%)
Commercial 399
(38.2%)
Commercial 237
(37.6%)
Medicaid 100 (9.6%) Medicaid 55 (8.7%)
Other 19 (1.8%) Other 12 (1.9%)
Current Smoker 427 (40.9%) 280 (44.4%)
Hypertension 854 (81.7%) 486 (77.1%)
Peripheral Vascular Disease 119 (11.4%) 58 (9.2%)
Myocardial Infarction 499 (47.8%) 288 (45.7%)
Congestive Heart Failure 144 (13.8%) 75 (11.9%)
Minimally Invasive CABG** 334 (32%) 232 (36.8%)
Median Sternotomy CABG 711 (68%) 398 (63.2%)
Emergent Procedure 26 (2.5%) 15 (2.4%)
Urgent Procedure 749 (71.7%) 450 (71.4%)
Elective Procedure 270 (25.8%) 165 (26.2%)
Number of Vessels
Revascularized
Mean 3.2 ± 1.2 Mean 3.1 ± 1.2
BMI kg/m
2*** Mean 29.3 ± 5.7 Mean 28.3 ± 5.2
Underweight 8
(0.8%)
Underweight 3
(0.5%)
Normal 238 (22.9%) Normal 173 (27.6%)
Overweight 385
(37%)
Overweight 247
(39.4%)
Obese 410 (39.4%) Obese 204 (32.5%)
BMI - Body Mass Index; CABG - Coronary Artery Bypass Graft; *No known
previous history of diabetes; **Coronary Artery Bypass Grafting via small left
thoracotomy; ***Underweight = less than 16.5 kg/m
2, Normal = 16.4-18.4 kg/
m
2, Overweight = 18.5-24.9 kg/m
2, Obese = 25.0 kg/m
2 and above.
Table 2 Frequency of normal and elevated HbA1c among all CABG patients and among those CABG patients with no
known history of diabetes
Pre-operative HbA1c Category All Patients (N = 1,045) No known history of DM (n = 630)
< 5.7% 222 (21.2%) 207 (32.9%)
5.7-6.4% 439 (42.0%) 356 (56.5%)
≥ 6.5% 384 (36.8%) 67 (10.6%)
DM - Diabetes mellitus.
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going CABG, 60% of those without a diabetes history
were diagnosed with dysglycemia using the OGTT [18].
In a study measuring HbA1c levels among 163 non-dia-
betic patients undergoing CABG, HbA1c was 6.0% or
higher in 93/163 (57%) patients and 7% or higher in 19/
163 (12%) patients [19]. Our study, using a larger sam-
ple size, is consistent with these findings and indicates
substantial case-finding when the HbA1c is used to
identify abnormalities. Still, to our knowledge, there has
not been a national or global systematic effort to pro-
mote either HbA1c or glucose based testing among
patients undergoing coronary bypass surgery.
In a recent report of National Health and Nutrition
Examination Survey (NHANES) data, the frequency of
Hba1c newly identified DM among the USA adult popu-
lation was 1.8%, a rate much lower than our findings
[20]. This difference may in part be explained by the
high frequency of multiple risk factors for pre-DM and
DM in our study population. Still, it is not clear why
newly diagnosed diabetic patients undergoing CABG
have not been previously informed of having diabetes,
especially since chronic medical problems such as
hypertension, hyperlipidemia and coronary artery disease
were fairly common. Most the study patients had health
care insurance, and would have the potential to access
and use primary and preventive care. It is possible that
the inconvenience and preparation needed for glucose
based testing leads to missed cases and fewer diagnoses.
The recent ADA recommendation of using HbA1c as
an alternative test to identify diabetes, which does not
require an overnight fast and can be obtained at any
time, may provide greater opportunity for diagnosis in a
wider range of clinical settings and eventually lead to
fewer undiagnosed individuals.
Diabetes screening most typically occurs during outpa-
tient primary or medical care visits, particularly since
long term follow-up and care will be needed. As our
findings suggest, this should not preclude screening in a
high risk population in an acute care setting. Patients
presenting for cardiac surgery could be screened pre-
operatively and the results used to inform the treating
surgeon of undiagnosed dysglycemia. As the evidence of
HbA1c as a short-term prognostic marker in CABG
Table 3 Comparison of clinical variables by HbA1c in patients without known diabetes (n = 630)
HbA1c (%) No DM
< 5.7 (n = 207)
Increased risk for DM
5.7-6.4 (n = 356)
DM
≥ 6.5 (n = 67)
P value
Age (years) Mean 64.6 ± 12.3 Mean 65.8 ± 10.6 Mean 64.9 ± 9.9 0.592
Female 38 (18.4%) 89 (25.0%) 21 (31.3%) 0.055
Male 169 (81.6%) 267 (75.0%) 46 (68.7%)
Race Caucasian 195 (94.0%) Caucasian 316 (88.8%) Caucasian 60 (89.6%) 0.970
Black 3 (1.5%) Black 14 (3.9%) Black 2 (3.0%)
Asian 0 Asian 7 (2.0%) Asian 2 (3.0%)
Other 9 (4.4%) Other 19 (5.3%) Other 1 (1.5%)
Insurance Status Medicare 101 (48.8%) Medicare 194 (54.5%) Medicare 31 (46.3%) 0.479
Commercial 82 (39.6%) Commercial 127 (35.7%) Commercial 28 (41.8%)
Medicaid 18 (8.7%) Medicaid 29 (8.2%) Medicaid 8 (11.9%)
Other 6 (2.9%) Other 6 (1.7%) Other 0
Current Smoker 92 (44.4%) 160 (45.0%) 28 (41.8%) 0.893
Hypertension 158 (76.3) 277 (77.8%) 51 (76.1%) 0.902
Peripheral Vascular Disease 21 (10.1%) 29 (8.2%) 8 (11.9%) 0.523
Myocardial Infarction 84 (40.6%) 170 (47.8%) 34 (50.8%) 0.176
Congestive Heart Failure 24 (11.6%) 38 (10.7%) 13 (19.4%) 0.127
Dyslipidemia 148 (71.5%) 265 (74.4%) 52 (77.6%) 0.564
Minimally Invasive CABG* 83 (40.1%) 131 (36.0%) 18 (26.9%) 0.149
Median Sternotomy CABG 124 (59.9%) 225 (63.2%) 49 (73.1%) 0.149
Emergent Procedure 3 (1.5%) 9 (2.5%) 3 (4.5%)
Urgent Procedure 153 (73.9%) 243 (68.3%) 54 (80.6%)
Elective Procedure 51 (24.6%) 104 (29.2%) 10 (15.0%) 0.420
Number of Vessels Revascularized Mean 3.1 ± 1.14 Mean 3.1 ± 1.14 Mean 3.6 ± 1.16 0.009
BMI (%) Mean 27.7 ± 4.9 Mean 28.5 ± 5.4 Mean 29.5 ± 5.4 0.031
BMI - Body Mass Index; CABG - Coronary Artery Bypass Graft; DM - Diabetes Mellitus; *Coronary Artery Bypass Grafting via small left thoracotomy.
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needed to optimize perioperative care and prevention of
post-operative complications; this remains to be pro-
spectively investigated. In addition, further study is
needed to determine if pre-operative normalization of
the HbA1c confers short or long-term post-operative
benefit.
Post-operatively, patients with abnormal HbA1c could
be referred for outpatient follow-up, a medical consult
or a session with a diabetes nurse educator could take
place prior to discharge. Emphasis on the management
of other contributory comorbiditites in this population
may further help in preventing progression of underly-
ing medical disease. While counseling the management
of chronic disease may be challenging in acute care set-
tings, individuals will sometimes show greater interest in
their health during times of illness and opportunities for
early diagnosis should not be lost. During a brief discus-
sion patients with elevated HbA1c could be encouraged
to partner with a provider and maintain long term care
as well as attempt life-style modifications. The concept
of the ‘teachable moment’ has been demonstrated in the
case of smoking cessation - patients are more likely to
quit smoking following health events, such as pregnancy,
hospitalizations, or diagnosis of cancer [21]. Such health
events represent opportunities for health care providers
to educate patients and encourage behavior modifica-
tions. Medical triggers are associated with better short-
and long-term weight loss, which could be one compo-
nent of a diabetes intervention [22].
Conclusion
In conclusion, our study found a high prevalence of dys-
glycemia in patients undergoing CABG without a prior
history of diabetes. These findings suggest that all
patients with no known history of diabetes undergoing
CABG should be screened for dysglycemia, particularly
as it has been recently reported as an independent risk
for post-operative complications and adverse outcomes.
Further, an abnormal HbA1c warrants an inpatient or
post-discharge medical referral to initiate treatment and
help prevent long-term complications.
List of abbreviations
CAD: Coronary Artery Disease; CABG: Coronary Artery Bypass Grafting; ADA:
American Diabetes Association; DM: Diabetes mellitus; HbA1c: Hemoglobin
A1C; STS: Society of Thoracic Surgeons; BMI: Body Mass Index; OGTT: Oral
Glucose Tolerance Testing
Acknowledgements
We acknowledge the cardiothoracic surgery team, clinical staff and
pharmacy team at Staten Island University Hospital and North Shore Long
Island Jewish Health System for their help in obtaining HbA1c and clinical
data; the volunteers who assisted with data collection: Ankit Christie,
Jonathan DeAssis, Korrine Compton, and Loren Trapanese; the pharmacy
students for their help in data organization: Chris Kalasithasa, Jonathan
Horvath and Kevin Kalarithasa; and Ricardo Crosby in extracting the data
points from the Centricity DMS STS database. Special thanks to Nancy Hogle,
RN and Dr John P Nabagiez for their help in applying final touches to this
project.
Author details
1Cardiothoracic Surgery Department, Heart Institute at Staten Island
University Hospital, 475 Seaview Ave, Staten Island, New York, USA.
2State
University of New York Health Science Center at Brooklyn, 450 Clarkson
Avenue, Brooklyn, New York, USA.
3Department of Internal Medicine, Staten
Island University Hospital, 475 Seaview Ave, Staten Island, New York, USA.
4Pharmacy Clinic, Long Island University, Brooklyn, New York, USA.
5Krasnoff
Quality Management Institute, North Shore-Long Island Jewish Health
System, 600 Northern Boulevard, Great Neck, New York, USA.
6Department of
Emergency Medicine, Long Island Jewish Medical Center, North Shore-Long
Island Jewish Health System, 270-05 76th Avenue, New Hyde Park, New
York, USA.
7Hofstra North Shore-LIJ School of Medicine, Hofstra University,
Hempstead, New York, USA.
Authors’ contributions
RAS developed the study concept, supervised the data analysis and drafted
the manuscript. JTM designed the protocol, contributed to the discussion,
and reviewed/edited the manuscript. MAS researched the data, contributed
to the discussion, and reviewed/edited the manuscript. AME analyzed and
researched data. MF collected data and reviewed/edited the manuscript.
TMB, BA, EQ, WJM, and YDD contributed to the discussion and reviewed/
edited the manuscript.
All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 17 May 2011 Accepted: 2 September 2011
Published: 2 September 2011
References
1. Bartnik M, Rydén L, Ferrari R, Malmberg K, Pyörälä K, Simoons M, Standl E,
Soler-Soler J, Ohrvik J, Euro Heart Survey Investigators: The prevalence of
abnormal glucose regulation in patients with coronary artery disease
across Europe. The Euro Heart Survey on diabetes and the heart. Eur
Heart J 2004, 25(21):1880-90.
2. Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis:
epidemiology, pathophysiology and management. JAMA 2002,
287(19):2570-2581.
3. Creager MA, Luscher TF, Cosentino F, Beckman JA: Diabetes and vascular
disease: pathophysiology, clinical consequences and medical therapy:
Part 1. Circulation 2003, 108(12):1527-1532.
4. Milicevic Z, Raz I, Beattie SD, Campaigne BN, Sarwat S, Gromniak E,
Kowalska I, Galic E, Tan M, Hanefeld M: Natural History of cardiovascular
disease in patients with diabetes: role of hyperglycemia. Diabetes Care
2008, 31(Suppl 2):S155-S160.
5. Kannel WB, McGee DL: Diabetes and cardiovascular risk factors: The
Framingham Study. Circulation 1979, 59(1):8-13.
6. Laakso M: Hyperglycemia and cardiovascular disease in type 2 diabetes.
Diabetes 1999, 48(5):937-942.
7. Danaei G, Friedman AB, Oza S, Murray CJ, Ezzati M: Diabetes prevalence
and diagnosis in US states: analysis of health surveys. Popul Health Metr
2009, 7:16.
8. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM,
Walker EA, Nathan DM, Diabetes Prevention Program Research Group:
Reduction in the incidence of type 2 diabetes with life style intervention
or metformin. N Engl J Med 2002, 346(6):393-403.
9. Executive Summary: Standards of Medical Care in Diabetes–2010.
Diabetes Care 2010, 33(Suppl 1):S4-10.
10. Halkos ME, Lattouf OM, Puskas JD, Kilgo P, Cooper WA, Morris CD,
Guyton RA, Thourani VH: Elevated pre-operative hemoglobin A1c level is
associated with reduced long-term survival after coronary artery bypass
surgery. Ann Thorac Surg 2008, 86(5):1431-7.
11. Medhi M, Marshall MC Jr, Burke HB, Hasan R, Nayak D, Reed G, LaFaro R,
Southren AL: HbA1c predicts length of stay in patients admitted for
coronary artery bypass surgery. Heart Dis 2001, 3(2):77-9.
McGinn et al. Journal of Cardiothoracic Surgery 2011, 6:104
http://www.cardiothoracicsurgery.org/content/6/1/104
Page 5 of 612. Alserius T, Anderson RE, Hammar N, Nordqvist T, Ivert T: Elevated
glycosylated haemoglobin (HbA1c) is a risk marker in coronary artery
bypass surgery. Scand Cardiovasc J 2008, 42(6):392-8.
13. Hu DY, Pan CY, Yu JM, China Heart Survey Group: The relationship
between coronary artery disease and abnormal glucose regulation in
China: the China heart survey. Eur Heart J 2006, 27(21):2573-79.
14. Okosieme OE, Peter R, Usman M, Bolusani H, Suruliram P, George L,
Evans LM: Can admission and fasting glucose reliably identify
undiagnosed diabetes in patients with acute coronary syndrome?
Diabetes Care 2008, 31(10):1955-59.
15. Norhammer A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L,
Malmberg K: Glucose metabolism in patients with acute myocardial
infarction and no previous diagnosis of diabetes mellitus: a prospective
study. Lancet 2002, 359(9324):2140-44.
16. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V,
Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M,
Verheugt F, Weidinger F, Weis M, ESC Committee for Practice Guidelines
(CPG), Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G,
Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U,
Silber S, Tendera M, Widimsky P, Zamorano JL, Silber S, Aguirre FV, Al-
Attar N, Alegria E, Andreotti F, Benzer W, Breithardt O, Danchin N, Di
Mario C, Dudek D, Gulba D, Halvorsen S, Kaufmann P, Kornowski R, Lip GY,
Rutten F: Management of acute myocardial infarction in patients
presenting with persistent ST-segment elevation: the Task Force on the
Management of ST-Segment Elevation Acute Myocardial Infarction of
the European Society of Cardiology. Eur Heart J 2008, 29(23):2909-2945.
17. Anderson RE, Brismar K, Ivert T: Only a minority of patients referred for
elective coronary artery bypass surgery have risk factors diagnosed and
treated according to established guidelines. Diab Vasc Dis Res 2007,
4(2):112-116.
18. Tekumit H, Cenal AR, Polat A, Uzun K, Tataroglu C, Akinci E: Diagnostic
value of hemoglobin A1c and fasting plasma glucose levels in coronary
artery bypass grafting patients with undiagnosed diabetes mellitus. Ann
Thorac Surg 2010, 89(5):1482-1487.
19. Engoren M, Habib RH, Zacharias A, Schwann TA, Riordan CJ, Durham SJ,
Shah A: The prevalence of elevated hemoglobin A1c in patients
undergoing coronary artery bypass surgery. J Cardiothorac Surg 2008,
3:63.
20. Cowie CC, Rust KF, Byrd-Holt DD, Gregg EW, Ford ES, Geiss LS,
Bainbridge KE, Fradkin JE: Prevalence of diabetes and high risk for
diabetes using A1C criteria in the U.S. population in 1988-2006. Diabetes
Care 2010, 33(3):562-8.
21. McBride CM, Emmons KM, Lipkus IM: Understanding the potential of
teachable moments: the case of smoking cessation. Health Educ Res 2003,
18(2):156-70.
22. Gorin AA, Phelan S, Hill JO, Wing RR: Medical triggers are associated with
better short- and long-term weight loss outcomes. Prev Med 2004,
39(3):612-6.
doi:10.1186/1749-8090-6-104
Cite this article as: McGinn et al.: Prevalence of Dysglycemia Among
Coronary Artery Bypass Surgery Patients with No Previous Diabetic
History. Journal of Cardiothoracic Surgery 2011 6:104.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
McGinn et al. Journal of Cardiothoracic Surgery 2011, 6:104
http://www.cardiothoracicsurgery.org/content/6/1/104
Page 6 of 6